Continuum Advisory’s Takeda Pharmaceutical TAK Stock Holding History

Continuum Advisory’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-407	Closed	-$5.39K	–	1916
2024 Q4	$5.39K	Sell	407 -248	-38%	-$3.41K	﹤0.01%	1120
2024 Q3	$8.89K	Sell	655 -210	-24%	-$2.98K	﹤0.01%	1031
2024 Q2	$11.2K	Sell	865 -167	-16%	-$2.21K	﹤0.01%	913
2024 Q1	$13.8K	Buy	+1,032	New	+$15K	﹤0.01%	868

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Continuum Advisory's TAK Position: Q1 2025 in Review

Continuum Advisory sold out of Takeda Pharmaceutical (TAK) in Q1 2025, closing a stake of 407 shares — an estimated $5.39K sold.

Continuum Advisory first reported a position in TAK in Q1 2024 and held it in 4 quarters. The position peaked at $13.8K in Q1 2024. 307 funds tracked by Wall St. Rank hold TAK as of Q1 2025.

Continuum Advisory reported no remaining Takeda Pharmaceutical position as of Q1 2025 after selling out during the quarter.
Continuum Advisory sold 407 Takeda Pharmaceutical shares in Q1 2025, an estimated $5.39K.
Continuum Advisory first reported a position in Takeda Pharmaceutical in Q1 2024 and held it in 4 quarters.
Continuum Advisory's Takeda Pharmaceutical position peaked at $13.8K in Q1 2024.
307 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.